Results 21 to 30 of about 3,500 (185)

Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis. [PDF]

J Crohns Colitis, 2023
Gros B, Goodall M, Plevris N, Constantine-Cooke N, Elford AT, O'Hare C, Noble C, Jones GR, Arnott ID, Lees CW.   +9 more
europepmc   +4 more sources

Filgotinib: First Approval [PDF]

Drugs, 2020
Filgotinib (Jyseleca®) is an oral, ATP-competitive, reversible JAK1 preferential inhibitor that is being developed by Galapagos NV and Gilead Sciences for the treatment of inflammatory autoimmune diseases, including inflammatory arthritis and inflammatory bowel disease.
Dhillon, Sohita, Keam, Susan J.
openaire   +2 more sources

Rheumatoid Arthritis Preceded by Interstitial Lung Disease Controlled by Long‐Term Treatment With the Janus Kinase 1‐Selective Inhibitor, Filgotinib: A Case Report [PDF]

Respirol Case Rep
We present a case of ILD preceding RA onset. The disease activity of arthritis and ILD was controlled, and ILD was stabilised for 4 years with the JAK1 selective inhibitor, filgotinib. ABSTRACT We present a case of active interstitial lung disease (ILD) preceding the onset of rheumatoid arthritis (RA).
Sato T, Nakazawa S, Yamamoto S, Nagatani K, Sato K.   +4 more
europepmc   +2 more sources

Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects

Clinical and Translational Science, 2022
Filgotinib, a preferential Janus Kinase‐1 inhibitor, is approved in Europe and Japan for treatment of rheumatoid arthritis and is being developed for treatment of other chronic inflammatory diseases. Three drug‐drug interactions studies were conducted in
Chia‐Hsiang Hsueh, Kacey Anderson, Gong Shen, Chohee Yun, Ann Qin, Ahmed A. Othman   +5 more
doaj   +1 more source

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial [PDF]

Intestinal Research, 2023
Background/Aims The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial.
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe   +15 more
doaj   +1 more source

Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. [PDF]

, 2017
Pathogenesis of cutaneous extraintestinal manifestations [EIM] in inflammatory bowel disease [IBD] remains elusive. Efficacy of anti-TNF agents suggests TNF-dependent mechanisms.
Biedermann, L., Dawson, H., Galván, J.A., Greuter, T., Lugli, A., Navarini, A., Prinz Vavricka, M.B., Rogler, G., Scharl, M., Schoepfer, A.M., Soltermann, A., Terracciano, L., Vavricka, S.R., Zlobec, I.   +13 more
core   +7 more sources

Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy

RMD Open, 2020
Objectives Patients with lupus membranous nephropathy (LMN) are at risk for prolonged proteinuria and progressive chronic kidney disease. There are no proven effective treatments for LMN, and controlled trials are lacking.
Sam Lim, Matthew Baker, Vimal Derebail, Yashaar Chaichian, Mark Genovese, Panduranga Rao, Winn Chatham, Michael Bubb, Hooman Hajian, Oksana Gurtovaya, Uptal Patel, James Tumlin   +11 more
doaj   +1 more source

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial [PDF]

, 2022
INTRODUCTION Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the partial Mayo Clinic Score (pMCS) and component patient-reported subscores to assess the rapidity and ...
Danese, Silvio, Dinoso, Jason, Feagan, Brian G, Ferrante, Marc, Hibi, Toshifumi, Hsieh, Jeremy, Le Brun, Franck-Olivier, Loftus, Edward V, Oortwijn, Alessandra, Peyrin-Biroulet, Laurent, Ritter, Timothy, Rogler, Gerhard, Sandborn, William J, Schreiber, Stefan, Vermeire, Séverine, Yun, Chohee   +15 more
core   +2 more sources

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate

Rheumatology and Therapy, 2023
Introduction Our aim was to evaluate protein biomarker changes related to the administration of filgotinib, a Janus kinase (JAK) 1 preferential inhibitor, in patients with moderately to severely active rheumatoid arthritis (RA) with inadequate response ...
Yoshiya Tanaka, Peter C. Taylor, Emon Elboudwarej, Angie Hertz, Xiaorong Shao, Vladislav A. Malkov, Hironori Matsushima, Kahaku Emoto, Bryan Downie, Tsutomu Takeuchi   +9 more
doaj   +1 more source

Filgotinib: A Clinical Pharmacology Review

Clinical Pharmacokinetics, 2022
Filgotinib (GS-6034, formerly GLPG0634; Jyseleca®) is an oral, preferential Janus kinase (JAK)-1 inhibitor. Preferential inhibition of JAK1 modulates a subset of proinflammatory cytokines within the JAK-signal transducer and activator of transcription pathway, which differ from those inhibited by JAK2 or JAK3.
Florence Namour, Kacey Anderson, Cara Nelson, Chantal Tasset   +3 more
openaire   +2 more sources